Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of AMG 193 in MTAP-deleted Advanced Non-Small Cell Lung Cancer
2024-514459-14-00Phase 2Authorised
- Sponsor
- Amgen
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 2, single-arm trial of anvumetostat in non-small cell lung cancer (NSCLC), sponsored by Amgen. Primary endpoints: Objective response (OR) by RECIST 1.1 (primary), Incidence of treatment-emergent adverse events (TEAEs), grade ≥ 3 TEAEs, serious adverse events (SAEs), and events of interest (EOIs) (primary) and 2 more. Planned start Apr 2025; status: authorised.
02
Drugs
anvumetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-514459-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514459-14-00.